The numbers
On 5 October 2025 Melbourne-based Heidi Health announced a US$65 million (A$98 million) Series B, taking the company's post-money valuation to US$465 million (A$704 million). The round was led by Point72 Private Investments, the venture arm of Steven A Cohen's hedge-fund group, with participation from existing investors Blackbird, Headline, and Latitude (the growth fund of Phoenix Court). Reporting in TechCrunch, SmartCompany, and Heidi's own press release confirms the lead, the syndicate, and the valuation.
Heidi was founded in 2021 (originally as Oscar) by Dr Thomas Kelly, a former vascular surgical resident, alongside Waleed Mussa (formerly Goldman Sachs) and Yu Liu (formerly Coles Group). The product is an AI medical scribe that transcribes clinician-patient conversations and produces clinical notes, referral letters, and follow-up assessments.
The clinician-founder pattern
Kelly's public framing of why he left training is consistent with the pattern most Australian clinician founders describe. In a December 2025 CNBC profile he ties the company's existence to a workflow he experienced thousands of times in tertiary care, the unstructured, error-prone moments around documentation and handover.
The structural feature worth noting is that the founder did not need to be the only clinical credibility on the cap table to underwrite the deal. By Series B, Heidi had clinicians from more than two hundred medical specialties using the platform across some seventy-three million patient consults, per the company's October press release. The clinical credibility moved from the founder's CV to the product's usage data. That is the trajectory clinician founders should plan toward.
The syndicate shape
The investor pattern at Heidi's Series B is instructive. A US institutional lead (Point72) anchors the round at the top of the table. An Australian venture firm (Blackbird) follows on from earlier rounds, signalling continuity. Two specialist growth funds (Headline, Latitude) participate at smaller cheque sizes, providing pricing discipline and reference capital.
For Australian clinician founders thinking about a Series B, the structural lesson is that the lead almost certainly comes from the US once the round size crosses the US$30 million mark. Local follow-on capital exists but rarely leads at that scale. Plan the syndicate accordingly. The sequencing implication: build relationships with US healthtech investors at Series A, not Series B, so that the lead conversation in the next round is not also a first conversation.
What the public record shows about preparation
Heidi's public statements emphasise the customer evidence the company brought to the round. Two hundred plus medical specialties. Seventy-three million consults processed. Active deployment across health systems and individual practices. None of this is the founder's narrative. All of it is the product's record. Investors at growth-stage rounds are pattern-matching against verifiable usage, not pitch-deck logic.
Heidi has also publicly flagged the regulatory questions that follow at scale. In a SmartCompany interview, Kelly highlighted the risk that healthcare AI can degrade under pressure if clinical safety frameworks are not built into the product from the outset. That is a clinician-founder argument that non-clinical founders rarely make in public, and it is the argument that compounds in the company's regulatory and enterprise-sales narrative.
Lessons for the next clinician founder
Three things that travel from this single public raise. First, the clinical workflow you have lived through is a real basis for a product, but it has to be expressed in usage data, not in personal experience, by the time the round is at growth stage. Second, the syndicate shape will rotate from Australian-led at seed to US-led at Series B, which has to be planned for at Series A. Third, regulatory and clinical-safety language is a competitive moat that clinician founders can credibly assert and that non-clinical founders cannot. Use it.
Sources
- 01TechCrunch, Heidi Health raises $65M Series B led by Steve Cohen's Point72 (5 Oct 2025)
- 02SmartCompany, Heidi Health's $98 million raise skyrockets its valuation to $704 million
- 03Heidi Health, Series B announcement (5 Oct 2025)
- 04Startup Daily, Heidi Health bags $98 million Series B at $703 million valuation
- 05CNBC, He left medicine to build an AI tool, now it's worth $460 million (24 Dec 2025)
- 06SmartCompany, Heidi Health CEO warns healthcare AI can degrade under pressure
Written by ASME Editorial · Published 8 Apr 2026